ISSN: 0929-1903

Journal Home

Journal Guideline

Cancer Gene Therapy Q1 Unclaimed

Nature Publishing Group United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Cancer Gene Therapy is a journal indexed in SJR in Molecular Biology and Molecular Medicine with an H index of 99. It has a price of 3490 €. It has an SJR impact factor of 1,457 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,457.

Cancer Gene Therapy focuses its scope in these topics and keywords: tumor, cancer, rna, cells, virus, gene, induces, targeting, necrosis, breast, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Molecular Biology (Q1) Molecular Medicine (Q1) Cancer Research (Q2)

Price

3490 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,457

SJR Impact factor

99

H Index

165

Total Docs (Last Year)

367

Total Docs (3 years)

9395

Total Refs

1780

Total Cites (3 years)

354

Citable Docs (3 years)

4.96

Cites/Doc (2 years)

56.94

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Cell Research Q1
Molecular Cell Q1
Cell Host and Microbe Q1
Annual Review of Plant Biology Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

Purging of human breast cancer cells from stem cell products with an adenovirus containing p53

Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity

The cellular oncogene EWS/activating transcription factor 1 is unable to activate adenovirus-borne promoters: Implications for cytotoxic prodrug therapy of malignant melanoma of soft parts

Development of a murine orthotopic model of leukemia: Evaluation of TP53 gene therapy efficacy

Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter

Expression of the prodrug-activating enzyme DT-diaphorase via Ad5 delivery to human colon carcinoma cells in vitro

Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells

Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer

Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures

A nonviral carrier for targeted gene delivery to tumor cells

Lipofection of early passages of cell cultures derived from murine adenocarcinomas: In vitro and ex vivo testing of the thymidine kinase/ganciclovir system

Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells

SHOW MORE ARTICLES

Transduction of murine colon carcinoma cells with interleukin-15 gene induces antitumor effects in immunocompetent and immunocompromised hosts

Enhanced antitumor effect of EGF R-targeted p21WAF-1 and GM-CSF gene transfer in the established murine hepatoma by peritumoral injection

Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis

Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer

Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA

Long-term effects of plasmid-mediated growth hormone releasing hormone in dogs

Bone marrow-derived cells as carriers of recombinant immunomodulatory cytokine genes to lymphoid organs

Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines

Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2

hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin

Identification of FGF receptor-binding peptides for cancer gene therapy

Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase gene